600381 Stock Overview
Qinghai Spring Medicinal Resources Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Qinghai Spring Medicinal Resources Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.08 |
| 52 Week High | CN¥8.43 |
| 52 Week Low | CN¥1.84 |
| Beta | 0.44 |
| 11 Month Change | 8.83% |
| 3 Month Change | -0.65% |
| 1 Year Change | -62.58% |
| 33 Year Change | -53.05% |
| 5 Year Change | -43.59% |
| Change since IPO | -85.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600381 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.6% | -0.6% | -2.8% |
| 1Y | -62.6% | -8.7% | 2.0% |
Return vs Industry: 600381 underperformed the CN Pharmaceuticals industry which returned -7.9% over the past year.
Return vs Market: 600381 underperformed the CN Market which returned 3.2% over the past year.
Price Volatility
| 600381 volatility | |
|---|---|
| 600381 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600381 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600381's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 173 | Xuefeng Zhang | www.verygrass.com |
Qinghai Spring Medicinal Resources Technology Co., Ltd. research and development, production, and sale of cordyceps products. It is also involved in the sale of beverages and aquatic products; advertising; and foreign investment business.
Qinghai Spring Medicinal Resources Technology Co., Ltd. Fundamentals Summary
| 600381 fundamental statistics | |
|---|---|
| Market cap | CN¥1.76b |
| Earnings (TTM) | -CN¥287.99m |
| Revenue (TTM) | CN¥251.20m |
7.0x
P/S Ratio-6.1x
P/E RatioIs 600381 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600381 income statement (TTM) | |
|---|---|
| Revenue | CN¥251.20m |
| Cost of Revenue | CN¥147.09m |
| Gross Profit | CN¥104.11m |
| Other Expenses | CN¥392.09m |
| Earnings | -CN¥287.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 41.44% |
| Net Profit Margin | -114.64% |
| Debt/Equity Ratio | 0% |
How did 600381 perform over the long term?
See historical performance and comparison